Warfarin dose related to apolipoprotein E (APOE) genotype

This publication has 43 references indexed in Scilit:

• The physiology of vitamin K nutriture and vitamin K‐dependent protein function in atherosclerosis
  Journal of Thrombosis and Haemostasis, 2004
• EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM
  Drug Metabolism and Disposition, 2004
• Compound heterozygous mutations in the γ‐glutamyl carboxylase gene cause combined deficiency of all vitamin K‐dependent blood coagulation factors
  British Journal of Haematology, 2004
• Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
  Thrombosis and Haemostasis, 2004
• Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
  The Pharmacogenomics Journal, 2003
• Pharmacogenetics of Warfarin Elimination and its Clinical Implications
  Clinical Pharmacokinetics, 2001
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
  The Lancet, 1999
• Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.
  Genome Research, 1995
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
  Chemical Research in Toxicology, 1992
• Abnormal in vivo metabolism of apolipoprotein E4 in humans.
  Journal of Clinical Investigation, 1986